Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes (Q45861973)

17 December 2017

title

Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes (English)

1 reference

17 December 2017

0 references

0 references

Parsons GB

1

1 reference

17 December 2017

Souza DW

2

1 reference

17 December 2017

Wu H

3

1 reference

17 December 2017

Yu D

4

1 reference

17 December 2017

Wadsworth SG

5

1 reference

17 December 2017

Gregory RJ

6

1 reference

17 December 2017

Armentano D

7

1 reference

17 December 2017

publication date

24 August 2006

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

38-48

1 reference

17 December 2017

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagon-like peptide-1 and satiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Therapeutic strategies based on glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagon-like peptide-1 plasmid construction and delivery for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

GLP-1 gene delivery for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Characterization of an adenovirus gene transfer vector containing an E4 deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagon physiology and pathophysiology in the light of new advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

7 January 2021

Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

7 January 2021

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

7 January 2021

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

7 January 2021

Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

7 January 2021

The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL/KsJ and C57BL/6J strains

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

7 January 2021

Novel cloning method for recombinant adenovirus construction in Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302842

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302842

1 reference

17 December 2017

Dimensions Publication ID

1018124634

0 references

1 reference

17 December 2017